Axsome Therapeutics, Inc. (AXSM)
Automate Your Wheel Strategy on AXSM
With Tiblio's Option Bot, you can configure your own wheel strategy including AXSM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AXSM
- Rev/Share 10.0124
- Book/Share 1.478
- PB 87.7405
- Debt/Equity 2.9462
- CurrentRatio 1.5686
- ROIC -0.6199
- MktCap 6471224834.0
- FreeCF/Share -2.4374
- PFCF -53.6982
- PE -25.9686
- Debt/Assets 0.3365
- DivYield 0
- ROE -3.5758
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AXSM | B. Riley Securities | -- | Buy | -- | $179 | Oct. 1, 2025 |
| Resumed | AXSM | Wells Fargo | -- | Overweight | -- | $163 | Sept. 3, 2025 |
| Resumed | AXSM | Morgan Stanley | -- | Overweight | -- | $190 | July 3, 2025 |
| Initiation | AXSM | Oppenheimer | -- | Outperform | -- | $185 | June 3, 2025 |
| Initiation | AXSM | Jefferies | -- | Buy | -- | $200 | April 7, 2025 |
| Initiation | AXSM | Deutsche Bank | -- | Buy | -- | $176 | Feb. 11, 2025 |
| Reiterated | AXSM | Mizuho | -- | Outperform | $124 | $122 | Dec. 31, 2024 |
| Initiation | AXSM | Wells Fargo | -- | Overweight | -- | $140 | Sept. 3, 2024 |
News
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.
Read More
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Axsome enters into a settlement agreement with Hikma Pharmaceuticals to resolve a patent litigation related to Sunosi.
Read More
Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs
Published: February 24, 2025 by: Benzinga
Sentiment: Positive
On Monday, Axsome Therapeutics, Inc. AXSM announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP inhibitors (most commonly used drugs for migraine) met its primary endpoint.
Read More
Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth
Published: February 18, 2025 by: Zacks Investment Research
Sentiment: Positive
AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.
Read More
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Positive
Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's Auvelity and Sunosi are crucial, with Auvelity expected to generate over 75% of 2025 revenues; as such, today's news is a significant win. Despite high competition in MDD and other markets, Axsome's pipeline, including AXS-07 and AXS-12, shows potential for substantial revenue growth.
Read More
Why Axsome Therapeutics Stock Is Soaring Today
Published: February 11, 2025 by: The Motley Fool
Sentiment: Positive
Shares of Axsome Therapeutics (AXSM 4.36%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m.
Read More
Earnings Preview: Axsome Therapeutics (AXSM) Q4 Earnings Expected to Decline
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038.
Read More
Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Axsome (AXSM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
Why Axsome Therapeutics Stock Is Skyrocketing Today
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Shares of Axsome Therapeutics (AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m.
Read More
About Axsome Therapeutics, Inc. (AXSM)
- IPO Date 2015-11-19
- Website https://www.axsome.com
- Industry Biotechnology
- CEO Herriot Tabuteau
- Employees 712